Market Update (NYSE:BMY): Bristol-Myers Squibb and Celldex Therapeutics Announce Clinical Trial Collaboration to Evaluate the Combination of Investigational Immunotherapies Nivolumab and Varlilumab

[Business Wire] – Bristol-Myers Squibb Company and Celldex Therapeutics, Inc. announced today that they have entered into a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of nivolumab, Bristol-Myers Squibb’s . . . → Read More: Market Update (NYSE:BMY): Bristol-Myers Squibb and Celldex Therapeutics Announce Clinical Trial Collaboration to Evaluate the Combination of Investigational Immunotherapies Nivolumab and Varlilumab Similar Articles: Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb Announces Retirement of Brian Daniels Company Update (NYSE:BMY): Bristol-Myers Squibb Ranks First on 2014 Best Corporate Citizens List Stock Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb and Samsung BioLogics Expand Manufacturing Agreement